Literature DB >> 7591147

Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

J S Silva1, G N Vespa, M A Cardoso, J C Aliberti, F Q Cunha.   

Abstract

Cell invasion by Trypanosoma cruzi and its intracellular replication are essential for continuation of the parasite life cycle and for production of Chagas' disease. T. cruzi is able to replicate in nucleated cells and can be killed by activated macrophages. Gamma interferon (IFN-gamma) is one of the major stimuli for the activation of macrophages and has been shown to be a key activation factor for the killing of intracellular parasites through a mechanism dependent upon nitric oxide (NO) biosynthesis. We show that although the addition of exogenous tumor necrosis factor alpha (TNF-alpha) does not potentiate the trypanocidal activity of IFN-gamma in vitro, treatment of resistant C57BI/6 mice with an anti-TNF-alpha monoclonal antibody increased parasitemia and mortality. In addition, the anti-TNF-alpha-treated animals had decreased NO production, both in vivo and in vitro, suggesting an important role for TNF-alpha in controlling infection. In order to better understand the role of TNF-alpha in the macrophage-mediating killing of parasites, cultures of T. cruzi-infected macrophages were treated with an anti-TNF-alpha monoclonal antibody. IFN-gamma-activated macrophages failed to kill intracellular parasites following treatment with 100 micrograms of anti-TNF-alpha. In these cultures, the number of parasites released at various time points after infection was significantly increased while NO production was significantly reduced. We conclude that IFN-gamma-activated macrophages produce TNF-alpha after infection by T. cruzi and suggest that this cytokine plays a role in amplifying NO production and parasite killing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591147      PMCID: PMC173696          DOI: 10.1128/iai.63.12.4862-4867.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi.

Authors:  F Plata
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

2.  Trypanosoma cruzi upregulates nitric oxide release by IFN-gamma-preactivated macrophages, limiting cell infection independently of the respiratory burst.

Authors:  G Metz; Y Carlier; B Vray
Journal:  Parasite Immunol       Date:  1993-12       Impact factor: 2.280

3.  Protective effects of specific antibodies in Trypanosoma cruzi infections.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

4.  Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi.

Authors:  E H De Titto; J R Catterall; J S Remington
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

5.  Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2.

Authors:  S G Reed; J A Inverso; S B Roters
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

6.  In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.

Authors:  S G Reed
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

7.  Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages.

Authors:  D L Granger; J B Hibbs; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi.

Authors:  J J Wirth; F Kierszenbaum; G Sonnenfeld; A Zlotnik
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

9.  Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.

Authors:  F Plata; J Wietzerbin; F G Pons; E Falcoff; H Eisen
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

10.  Nitrate synthesis in the germfree and conventional rat.

Authors:  L C Green; S R Tannenbaum; P Goldman
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

View more
  93 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 3.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

5.  Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection.

Authors:  Valéria R A Pereira; Virginia M B Lorena; Mineo Nakazawa; Carlos F Luna; Edimilson D Silva; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Milena B P Soares; Eridan M Coutinho; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  Parasitol Res       Date:  2005-04-27       Impact factor: 2.289

6.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

7.  Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans.

Authors:  María Carolina Amezcua Vesely; Constanza Rodríguez; Adriana Gruppi; Eva Virginia Acosta Rodríguez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

8.  TNF microsatellite alleles in Brazilian Chagasic patients.

Authors:  Viriato Campelo; Roberto O Dantas; Renata T Simões; Celso T Mendes-Junior; Sandra M B Sousa; Aguinaldo L Simões; Eduardo A Donadi
Journal:  Dig Dis Sci       Date:  2007-08-23       Impact factor: 3.199

9.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.